To determine if MEDI8897 reduces the amount of visits to see a medical professional due to a lower respiratory tract infection caused by RSV. We will be looking at this in healthy preterm infants entering their first RSV session.
To better understand the effects of breastfeeding on infant growth and development.
The collection of the research data we hope will help better screening, diagnosing procedures and treatment of brain injury in newborns and identify a connection between MR imaging and neurodevelopmental outcomes.
Body Composition in Newborns with MRI of Congenital Adrenal Hyperplasia (CAH).
Develop non-invasive measures to identify abnormal placental function in babies with and without congenital anomalies.
Data Collection only. By reviewing the charts of CAH infants who come to our facility for treatment, we hope to discover which treatments, all of which are standard of care, lead to better outcomes for patients (primarily in the first year of life).
The NEAT Study is about obesity, appetite, emotions, and how the brain develops in children. The study team is looking for volunteer youth to participate who are either healthy or have a clinical condition called Congenital Adrenal Hyperplasia (CAH).
This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered twice daily (bid) with breakfast and evening meals for28 weeks in approximately 81 pediatric subjects with classic congenital adrenal hyperplasia (CAH) due to21-hydroxylase deficiency. Eligible subjects will be randomly assigned in a 2:1 ratio (active:placebo) to either crinecerfont (25 mg bid via oral solution for subjects 10 to <20 kg, 50 mg bid via oral solution for subjects 20 to <55 kg, or 100 mg bid via oral capsules for subjects ≥55 kg) or matching placebo (oral solution placebo for subjects <55 kg and oral capsule placebo for subjects ≥55 kg). Dose assignment from Day 1 to Week 28 will be based on the subject’s weight at Day 1. After the 28-week placebo-controlled treatment period, there will be a 24-week, open-label treatment period, during which all subjects will receive crinecerfont at doses based on their Week 28 body weight.
1. To identify family members of people with type 1 diabetes that may be at risk for developing type 1 diabetes. 2. To monitor the metabolic and immunologic status of at-risk individuals. Eligible individuals will be offered enrollment in type 1 diabetes prevention studies. See website for more details https://www.trialnet.org/
